WeedMD Reports Second Quarter 2017 Results
Ryan Allway
August 30th, 2017
News, Top News
TORONTO, Aug. 30, 2017 (GLOBE NEWSWIRE) — WeedMD Inc. (WMD.V) (“WeedMD” or the “Company”), a federally licensed producer and distributor of medical cannabis, is pleased to announce its financial results for the period ended June 30, 2017, and to provide a corporate update.
Second Quarter 2017 Milestones:
| Completed Public Listing on the TSX Venture Exchange | • | |||||
| Secured License to Sell Medical Cannabis and Live Cannabis Plants | • | |||||
| Launched Patient Services and Started Registering Patients | • | |||||
| Secured License to Produce Cannabis Oil | • | |||||
| Shipped Live Cannabis Plants to Patients | • | |||||
| Commenced Sales and Reported First Quarter of Revenue | • |
“WeedMD is achieving every initiative provided to shareholders either on or ahead of schedule – a testament to our team that is committed to the success of the Company. We are hitting all of our licensing milestones, generating strong yields, maintaining costs in line with our budget and producing product that is exceeding our patients’ expectations. We are building our business and look forward to continuing to deliver value for all of our shareholders,” said Bruce Dawson-Scully, CEO of WeedMD.
Operational Highlights:
- Public listing on the TSX Venture Exchange on April 27th (see here): Commencement of trading on the TSX Venture Exchange under the ticker symbol “WMD” after a successful completion of the reverse take-over of Aumento Capital V Corporation.
- Sales license secured on April 28th (see here): WeedMD’s 25,620 sq. ft. indoor production facility in Aylmer, Ontario, is operating at full capacity and is currently on track to produce in excess of 1,200 kg of dried cannabis per annum. Yields and costs are consistently improving with each harvest. Patient registration officially began on May 31st (see here) and the Company has since been steadily increasing its patient base and sales.
- Selling clones to home grow patients under ACMPR on June 13th (see here): The Company is currently offering several strains for patients opting to grow their own medicinal cannabis and has structured its pricing to provide reasonable and affordable access to a variety of medical cannabis strains. WeedMD has developed and successfully rolled out a proprietary system for packaging and shipping live cannabis plants to patients.
- Partnership with Van der Pop to bring leading female-focused brand to Canada on June 15th (see here): This partnership brings WeedMD further along its strategic path of targeting unique and underserved demographics of the Canadian cannabis market. The Company expects to deliver medical cannabis under the Van der Pop brand to its Canadian patients starting in late 2017. Patients eager to interact with Van der Pop are encouraged to visit Tokyo Smoke’s new flagship location on Queen West, in Toronto, where Van der Pop merchandise is being prominently displayed (see here).
- License to produce cannabis oils secured on June 19th (see here): Since receiving an oil production license, WeedMD has successfully imported and commissioned a purpose-built high-throughput ethanol extraction machine from Germany and has already produced, packaged and tested several batches of oil.
- Acceleration of production and strain development: During the quarter, WeedMD successfully continued the ramp up and calibration of its operations, resulting in steadily increased production with decreased associated costs per gram. WeedMD also spent time developing its extensive genetic bank, with several new strains developed this quarter with the intention of making them commercially available throughout the remainder of 2017.
Financial Highlights:
| For the quarter ended | Jun 30, 2017 | Mar 31, 2017 | |||
| ($) | ($) | ||||
| Revenue | 235,659 | – | |||
| Adjusted operating loss | (1,280,046) | (1,070,369) | |||
| Loss per share (basic and fully diluted) | (0.08) | (0.05) | |||
| As At | Jun 30, 2017 | Dec 31, 2016 | |||
| Total Assets | 9,193,579 | 10,052,971 | |||
| Total Liabilities | 770,337 | 6,970,144 | |||
| Working Capital | 6,501,895 | 1,330,566 | |||
- WeedMD generated $235,659 of revenue in its first quarter of sales. Revenues were derived primarily from the sale of dried medical cannabis and live cannabis plants. The Company received its license from Health Canada to sell medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) on April 28, 2017, and most of these sales occurred in June.
- Adjusted operating loss in the quarter was ($1,280,046), as compared to ($1,070,369) in the prior quarter. The increase in adjusted operating loss is due to an increase in production and headcount, additional expenses associated with being a public company, and costs associated with the launch of patient services and marketing due to the commencement of sales. Adjusted operating loss is a non-IFRS measure which has been implemented to remove non-cash and non-recurring expenditures to provide a better indication of ongoing performance.
- Cash of $3,968,371 at the end of the period, and Working Capital of $6,501,897.Management believes the Company has sufficient working capital to maintain its existing operations through the summer of 2018.
“Momentum in Q2 is being carried into Q3 with WeedMD continuing to execute towards its vision of becoming a leader in niche and underserved seniors and female demographics within the burgeoning Canadian cannabis market,” said Bruce Dawson-Scully. “We are leveraging management’s deep industry expertise and relationships in the seniors, assisted-living and long-term care industries. The Company is making significant strides in securing initial supply contracts in long-term care with our proprietary integrated care program. In addition, the Company is working on a very compelling expansion opportunity to position the company strategically ahead of the future adult-use market.”
For more information on WeedMD, access our investor presentation on our website here.
This press release should be read alongside WeedMD’s unaudited Financial Statements and Management’s Discussion and Analysis Report, which can be found under the Company’s profile at www.sedar.com. WeedMD’s unaudited Financial Statements and Management’s Discussion and Analysis Report have been filed with Canadian Securities Regulators.
About WeedMD Inc.
WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). WeedMD operates a 26,000-square foot, scalable production facility in Aylmer, Ontario with four acres of property for future expansion. WeedMD is focused on providing consistent, quality medicine to the long-term care and assisted living markets in Canada through its comprehensive platform developed exclusively for that industry. WeedMD is dedicated to educating healthcare practitioners and furthering public understanding of the role medical cannabis can play as a viable alternative to prescription medication in relieving a variety of chronic medical conditions and illnesses.
Follow WeedMD on:
Facebook: https://www.facebook.com/weedmd/
LinkedIn: https://www.linkedin.com/company-beta/5020743/
Twitter: https://twitter.com/WeedMD
Instagram: https://www.instagram.com/weedmd/
Forward-Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation which are based upon WeedMD’s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, WeedMD does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for WeedMD to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in WeedMD’s Management Discussion and Analysis for the six-month period ended June 30, 2017 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in WeedMD’s Management Discussion and Analysis could cause actual events or results to differ materially from those described in any forward-looking information.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE
For further information, please contact: WeedMD Inc. Keith Merker, Chief Financial Officer Tel: 519-765-2440 Ext. 222 Email: investor@weedmd.com To learn more, visit us at www.weedmd.com
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Rubicon Holdings, Inc., a Washington State corporation, is a cannabis company focused on the United States adult use and medical marijuana markets.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
